Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month High on Analyst Upgrade

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) reached a new 52-week high on Monday after Royal Bank Of Canada raised their price target on the stock from $8.00 to $9.00. Royal Bank Of Canada currently has an outperform rating on the stock. Aurinia Pharmaceuticals traded as high as $11.19 and last traded at $11.43, with a volume of 574650 shares traded. The stock had previously closed at $10.49.

Separately, HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at $27,000. Tower Research Capital LLC TRC raised its stake in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $31,000. GAMMA Investing LLC raised its stake in shares of Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares in the last quarter. Finally, MAI Capital Management bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at about $39,000. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Trading Up 9.2%

The business’s 50 day moving average is $8.35 and its two-hundred day moving average is $8.14. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.51 billion, a P/E ratio of 26.63 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.